Abstract
Abstract
Background
The impact of prostate radiotherapy on patient-reported health-related quality of life (HRQoL) significantly influences the outcomes of metastatic prostate cancer. We measured and compared HRQoL of metastatic prostate cancer patients who received cytoreductive prostate radiotherapy.
Methods
Between November 23, 2020, and November 21, 2022, we recruited 70 metastatic prostate cancer patients at the Department of Clinical Oncology at Suez Canal University Hospital. Patients were eligible if they had synchronous and metachronous histopathological confirmed metastatic adenocarcinoma and an Eastern Cooperative Oncology Group performance status ≤ 2. Random allocation was performed for either definitive local radiotherapy concurrent with the standard androgen deprivation therapy (ADT) or to the standard ADT alone. Definitive radiotherapy was delivered conventionally (70 Gy/35 fractions) or through the hypofractionated regimen (55 Gy/20 fractions). Patients completed the comprehensive European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-PR25) at baseline, then at three-month intervals for one year. The primary endpoint was patient-reported HRQoL, with secondary endpoints including toxicity and radiographic progression-free survival (rPFS). Mean HRQoL scores between groups were compared using the independent samples t-test.
Results
We observed clinically significant improvements in urinary and bowel functions between baseline, 3-month, 6-month, and 12-month intervals after receiving definitive prostate radiotherapy. Patients in the radiotherapy group had significantly lower urinary symptoms scores than the control group. However, sexual activity and functioning showed significant deterioration.
Conclusion
Cytoreductive prostate radiotherapy in metastatic prostate cancer patients significantly improved urinary functioning, preserved bowel functioning but was associated with worsening of sexual functioning.
Trial Registration
This trial was registered on (27/04/2023) with pactr.samrc.ac.za, PACTR202305854600529, URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25510
Publisher
Research Square Platform LLC
Reference22 articles.
1. Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics. 2023. CA Cancer J Clin. 2023;73(1):17–48. Available from: https://doi.org/10.3322/caac.21763.
2. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017;Siegel DA;MMWR Morb Mortal Wkly Rep,2020
3. Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y et al. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605–16. Available from: https://www.sciencedirect.com/science/article/pii/S2588931122000657.
4. Houédé N, Rébillard X, Bouvet S, Kabani S, Fabbro-Peray P, Trétarre B et al. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: An observational case-control study. BMC Cancer. 2020;20(1):757. Available from: https://doi.org/10.1186/s12885-020-07244-y.
5. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical tria;Boevé LMS;Eur Urol,2019